Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 3/20 | 0.32 |
| ▸ | MMP1 | P03956 | 2/20 | 0.32 |
| ▸ | MMP2 | P08253 | 2/20 | 0.32 |
| ▸ | MMP3 | P08254 | 1/20 | 0.32 |
| ▸ | MMP7 | P09237 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14449048 | 1.00 | HCRTR1 (0.32) | HCRTR1HCRTR2MMP9MMP1MMP2 | |
| SCHEMBL13697137 | 1.00 | HCRTR1 (0.32) | HCRTR1HCRTR2MMP9MMP1MMP2 | |
| SCHEMBL4087184 | 1.00 | HCRTR1 (0.32) | HCRTR1HCRTR2MMP9MMP1MMP2 | |
| SCHEMBL13696843 | 0.89 | MMP9 (0.32) | HCRTR1HCRTR2MMP9MMP1MMP2 | |
| SCHEMBL13696839 | 0.89 | MMP9 (0.32) | HCRTR1HCRTR2MMP9MMP1MMP2 | |
| SCHEMBL13696841 | 0.89 | MMP9 (0.32) | HCRTR1HCRTR2MMP9MMP1MMP2 | |
| SCHEMBL4157011 | 0.87 | MAPK1 (0.36) | — | |
| SCHEMBL5319489 | 0.87 | MAPK1 (0.36) | — | |
| SCHEMBL28442215 | 0.86 | HCRTR1 (0.32) | HCRTR1HCRTR2MMP9MMP1MMP2 | |
| SCHEMBL20789108 | 0.84 | HCRTR2 (0.31) | HCRTR1HCRTR2MMP9MMP1MMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090221811-A1 | PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES | CHEMAGIS LTD. (IL) | 2009-09-03 | — | — | US | claimed |
| WO-2007092705-A2 | PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES | CHEMAGIS LTD. (IL) | 2007-08-16 | — | — | WO | claimed |
| US-20070191598-A1 | Process for Preparing Gemcitabine and Associated Intermediates | CHEMAGIS LTD. (IL) | 2007-08-16 | — | — | US | claimed |
| CN-113784721-A | High activity compound for resisting COVID-19 | 阿堤亚制药公司 | 2021-12-10 | — | — | CN | disclosed |
| EP-3897668-A1 | HIGHLY ACTIVE COMPOUNDS AGAINST COVID-19 | ATEA Pharmaceuticals, Inc. (US) | 2021-10-27 | — | — | EP | disclosed |
| EP-2049558-B1 | NAPHTHALENE 2-CARBOXYLATE DERIVATIVE USEFUL FOR SYNTHESIZING GEMCITABINE AND A METHOD FOR PREPARING THE SAME | YUIL PHARM TECH CO LTD (KR) | 2012-03-21 | — | — | EP | disclosed |
| US-20100010205-A1 | NAPHTHALENE 2-CARBOXYLATE DERIVATIVE USEFUL FOR SYNTHESIZING GEMCITABINE AND A METHOD FOR PREPARING THE SAME | YUIL PHARM TECH CO., LTD (KR) | 2010-01-14 | — | — | US | disclosed |
| US-20090221811-A1 | PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES | CHEMAGIS LTD. (IL) | 2009-09-03 | — | — | US | disclosed |
| US-20090221811-A1 | PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES | CHEMAGIS LTD. (IL) | 2009-09-03 | — | — | US | disclosed |
| US-20090069557-A1 | PREPARATION OF GEMCITABINE | DR. REDDY'S LABORATORIES LTD. (IN) | 2009-03-12 | — | — | US | disclosed |
| WO-2007092705-A3 | PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES | CHEMAGIS LTD (IL) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007092705-A2 | PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES | CHEMAGIS LTD. (IL) | 2007-08-16 | — | — | WO | disclosed |
| WO-2007092705-A2 | PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES | CHEMAGIS LTD. (IL) | 2007-08-16 | — | — | WO | disclosed |
| US-20070191598-A1 | Process for Preparing Gemcitabine and Associated Intermediates | CHEMAGIS LTD. (IL) | 2007-08-16 | — | — | US | disclosed |
| US-20070191598-A1 | Process for Preparing Gemcitabine and Associated Intermediates | CHEMAGIS LTD. (IL) | 2007-08-16 | — | — | US | disclosed |
| WO-2007070804-A2 | PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES | CHEMAGIS LTD. (IL) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010205-A1 | NAPHTHALENE 2-CARBOXYLATE DERIVATIVE USEFUL FOR SYNTHESIZING GEMCITABINE AND A METHOD FOR PREPARING THE SAME | NUDT1, DUT, UMPS | HCRTR1 4292/4885HCRTR2 4088/4885MMP9 4597/4885 |
| US-20090069557-A1 | PREPARATION OF GEMCITABINE | GMNN, TYMP, GDA | HCRTR1 4871/4885HCRTR2 4877/4885MMP9 2617/4885 |
| US-20070191598-A1 | Process for Preparing Gemcitabine and Associated Intermediates | DCTD, DPYD, THPO | HCRTR1 4183/4885HCRTR2 4135/4885MMP9 4700/4885 |
| US-20090221811-A1 | PROCESS FOR PREPARING GEMCITABINE AND ASSOCIATED INTERMEDIATES | THPO, DPYD, DCTD | HCRTR1 4187/4885HCRTR2 3765/4885MMP9 4697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.